Antipsychotic-drug-induced hyperprolactinemia: Physiopathology, clinical features and guidance;Hyperprolactinémies induites par les antipsychotiques: physiopathologie, clinique et surveillance

Encephale

Volumn 40, Issue 1, 2014, Pages 86-94

  Besnard, I ^a   Auclair, V ^a   Callery, G ^a   Gabriel Bordenave, C ^a   Roberge, C ^a  

^a Service Pharmacie   (France)

Author keywords

Antipsychotic agents; Guidelines; Hyperprolactinemia; Prolactin

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; RISPERIDONE;

ADENOHYPOPHYSIS; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL FEATURE; HUMAN; HYPERPROLACTINEMIA; PATHOPHYSIOLOGY; PROLACTIN RELEASE; PROLACTIN SECRETING CELL;

ANTIPSYCHOTIC AGENTS; CONDUITE À TENIR; GUIDELINES; HYPERPROLACTINEMIA; HYPERPROLACTINÉMIE; NEUROLEPTIQUES; PROLACTIN; PROLACTINE;

ANTIPSYCHOTIC AGENTS; BONE DENSITY; DOPAMINE; FEMALE; HUMANS; HYPERPROLACTINEMIA; HYPOGONADISM; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; PITUITARY GLAND, ANTERIOR; PITUITARY-ADRENAL SYSTEM; PROLACTIN; RECEPTORS, DOPAMINE D2; RISK FACTORS; SEX FACTORS;

EID: 84894419344     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2012.03.002     Document Type: Short Survey

References (43)

1. P.M. Haddad, and A. Wieck Antipsychotic-induced hyperprolactinaemia. Mechanism, clinical features and management Drugs 64 20 2004 2291 2314
2. S. Madhusoodanan, S. Parida, and C. Jimenez Hyperpprolactinemia associated with psychotropics - a review Hum Psychopharmacol Clin Exp 25 2010 281 297
3. P. Fitzgerald, and T. Dinan Prolactin and dopamine: what is the connection? A review article J Psychopharmacol 2 2008 12 19
4. B. Mestre, and C. Pasquier Hyperprolactinémies et antipsychotiques Inf Psychiatr 80 2 2004 147 151
5. G.P. Chrousos The hypothalamic-pituitary-adrenal axis and immune mediated inflammation N Engl J Med 332 1995 1351 1363
6. R.C. Pelever, D. Branford, and L. Citrome et al. Antipsychotics and hyperprolactinaemia: clinical recommendations J Psychopharmacol 22 Suppl 2 2008 98 103
7. S. Kapur, and P. Seeman Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis Am J Psychiatry 158 2001 360 369
8. J.C. Chou, R. Douyon, and P. Czobor et al. Change in plasma prolactin and clinical response to haloperidol in schizophrenic and psychoaffective disorder Psychiatry Res 81 1 1998 51 55
9. S. Smith, M.J. Wheeler, and R. Murray et al. The effects of antipsychotic-induced hyperprolactinaemia on hypothalamic-pipuitary-gonadal axis J Clin Pharmacol 22 2002 109 114
10. A.F. Breier, A.K. Malhotra, and S. Tung-Ping et al. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side-effects, and neuroendocrine response Am J Psychiatry 156 1999 294 298
11. C. Busche, and M. Shaw Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with atypical and typical antipsychotics J Psychopharmacol 21 2007 768 773
12. U. Halbreich, B.J. Kinon, and J.A. Gilmore et al. Elevated prolactin levels in patients with schizophrenia: mechanism and related adverse effects Psychoneuroendocrinol 28 Suppl 1 2003 53 67
13. K.S. Kim, C.U. Pae, and J.H. Chae et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone J Clin Psychiatry 63 2002 408 413
14. B.J. Kinon, J.A. Gilmore, and H. Liu et al. Prevalence of hyperprolactinaemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone Psychoneuroendocrinol 28 Suppl 2 2003 55 68
15. B.J. Kinon, J.A. Gilmore, and H. Liu et al. Hyperprolactinaemia in response to antipsychotic-drugs: characterization across comparative clinical trials Psychoneuroendocrinol 28 Suppl 2 2003 69 82
16. T. PAparrigopoulos, J. Liappas, and E. Tzavellas et al. Amisulpride-induced hyperprolcatinaemia is reversible following discontinuation Prog Neuro Psychopharmacol Biol Psychiatry 31 1 2007 92 96
17. A. Wieck, and P. Haddad Hyperporlactinaemia caused by antipsychotics drugs BMJ 324 2002 250 252
18. H.Y. Meltzer, and V.S. Fang The effect of neuroleptics on serum prolactin in schizophrenic patients Arch Gen Psychiatry 33 3 1976 279 286
19. J.L. Rivera, S. Lal, and P. Ettigi et al. Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups Clin Endocrinol (Oxf) 5 3 1976 273 282
20. P.J. Goodnick, L. Rodriguez, and O. Santana Antipsychotics: impact on prolactin levels Expert Opin Pharmacother 3 10 2002 1381 1391
21. R. Schlosser, G. Grunder, and I. Anghelescu et al. Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels Neuropsychobiology 46 1 2002 33 40
22. C. Cosi, E. Carilla-Durand, and M.B. Assie et al. Partial agonist properties of the antipsychotics SSR 181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release Eur J Pharmacol 535 2006 135 144
23. S.R. David, C.C. Taylor, and B.J. Kinon et al. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia Clin Ther 22 9 2000 1085 1096
24. H.Y. Meltzer, and G.A. Gudelsky Dopaminergic and serotonergic effects of clozapine. Implications for a unique clinical profile Arzneimittelforschung 42 2A 1992 268 272
25. K. Melkersson Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients J Clin Psychiatry 66 2005 761 767
26. M. Fric, and G. Laux Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics Psychiatr Prax 30 Suppl 2 2003 S97 S101
27. U. Wesselmann, and K. Windgassen Galactorrhea: subjective response by schizophrenic patients Acta Psychiatrica Scand 91 1995 152 155
28. C. Busche, D. Yeomans, and T. Floyd et al. Categorical prevalence and severity of hyperproalctinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics J Psychopharmacol 22 Suppl 2 2008 56 62
29. V. O'Keane Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia J Psychopharmacol 22 Suppl 2 2008 70 75
30. Société française d'endocrinologie. Diagnostic et prise en charge des hyperprolactinémies. Consensus d'experts de la Société française d'endocrinologie. Médecine clinique endocrinologie & diabète 2006:1-7. (Hors-série).
31. A. Klibanski, B.M. Biller, and D.I. Rosenthal et al. Effects of prolactin and estrogen deficiency in amenorrheic bone loss J Clin Endocrinol Metab 67 1 1988 124 130
32. J.C. Prior, Y.M. Vigna, and M.T. Schecter et al. Spinal bone loss and ovulatory disturbances N Engl J Med 323 1990 1221 1227
33. B.M.K. Biller, H.B.A. Baum, and D.I. Rosenthal et al. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea J Clin Endocrinol Metab 75 3 1992 692 697
34. U. Naidoo, D.C. Goff, and A. Klibanski Hyperprolactinemiaand bone mineral density: the potential impact of antipsychotic agents Psychoneuroendocrinol 28 suppl 2 2003 97 108
35. P.S. Wang, A.M. Walker, and M.T. Tsuang et al. Dopamine antagonists and the development of breast cancer Arch Gen Psychiatry 59 2002 1147 1154
36. P.N. Harvey, D.S. Everett, and C.J. Springall Adverse effects of prolactin in rodents and humans: breast and prostate cancer J Psychopharmacol 22 Suppl 2 2008 20 27
37. S.S. Tworoger, H. Eliassen, and P. Sluss et al. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer J Clin Oncol 25 2007 1482 1488
38. B.K. Vonderhaar Prolactin: the forgotten hormone in breast cancer Pharmacol Ther 79 1998 169 178
39. S.S. Tworoger, A.H. Eliassen, and B. Rosner et al. Plasma prolactin concentrations and risk of postmenopausal breast cancer Cancer Res 64 2004 6814 6819
40. S.S. Tworoger, P. Sluss, and S.E. Hankinson Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women Cancer Res 66 2006 2476 2482
41. R.I.G. Holt Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists J Psychopharmacol 22 Suppl 2 2008 28 37
42. M.E. Molitch Medication-induced hyperprolactinaemia Mayo Clin Proc 80 8 2005 1050 1057
43. B. Wistedt, D. Wiles, and T. Kolakowska Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatments with depot neuroleptics Lancet 317 1981 1163